Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Other Operating Expenses (2019 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Other Operating Expenses for 5 consecutive years, with $13.2 million as the latest value for Q4 2025.

  • For Q4 2025, Other Operating Expenses changed N/A year-over-year to $13.2 million; the TTM value through Dec 2025 reached $13.2 million, up 139.72%, while the annual FY2025 figure was $13.2 million, 139.72% up from the prior year.
  • Other Operating Expenses hit $13.2 million in Q4 2025 for Sangamo Therapeutics, up from $1.2 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $58.6 million in Q1 2023 and bottomed at $296000.0 in Q4 2023.
  • Average Other Operating Expenses over 3 years is $24.8 million, with a median of $13.2 million recorded in 2025.
  • On a YoY basis, Other Operating Expenses climbed as much as 92.57% in 2024 and fell as far as 97.72% in 2024.
  • Sangamo Therapeutics' Other Operating Expenses stood at $296000.0 in 2023, then skyrocketed by 295.95% to $1.2 million in 2024, then skyrocketed by 1029.27% to $13.2 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $13.2 million, $1.2 million, and $4.3 million for Q4 2025, Q2 2024, and Q1 2024 respectively.